摘要
目的探讨核苷酸切除修复基因家族成员ERCC1基因在乳腺癌中的表达情况和新辅助化疗对它的影响及临床意义。方法RT-PCR检测40例常规手术切除的乳腺癌标本和14例术前曾接受新辅助化疗的乳腺癌标本中ERCC1基因的表达。结果乳腺癌中ERCC1基因阳性表达率为35.0%,其表达水平与患者的年龄、肿瘤大小、淋巴结转移、病理分型、组织学分级、ER、PR和HER-2均无明显相关性(P>0.05)。新辅助化疗组ERCC1基因的表达水平明显高于无化疗组(P<0.05)。结论ERCC1基因的表达不影响乳腺癌的临床病理特征,新辅助化疗可以上调ERCC1基因的表达水平,在临床后续化疗中应予重视。
Objective To investigate the expression of ERCCI gene in breast cancer before and after neo-adjuvant chemotherapy. Methods The expression of ERCC 1 gene was detected by RT-PCR in 40 breast cancer patients and in 14 patients treated with neoadjuvant chemotherapy. Results Positive expression of ERCC 1 gene was detected by RT-PCR in 35.0% of the breast cancer specimens, and ERCCI expression was not correlated to the patients＇ age, tumor size, axillary lymph node metastasis, pathological type, histological grade, ER, PR or HER-2 （P〉0.05）. ERCCI gene expression was significantly higher in neo-adjuvant chemotherapy group than in non-chemotherapy group （P〈0.05）. Conclusion The expression of ERCC 1 gene does not affect the clinical and pathological features of breast cancer. Neo-adjuvant chemotherapy can increase the expression of ERCC 1 gene, due attention should be given to with in subsequent chemotherapy.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2008年第4期603-605,共3页
Journal of Southern Medical University
基金
深圳市科技局重点资助项目(200628)~~
